The strategy is to obtain drug efficacy data from human volunteers as early as possible in the drug development phase utilising human pain bio-markers and surrogate pain models to qualify go/no-go decisions as early as possible and to qualify the selection of the patient population (sub-population) which is most likely to respond to the compound. Such studies can be done for single dose, multiple dosing or in dose escalation studies. Adding experimental tests in early studies are for free at they can be done in addition to pharmacokinetic sampling and side-effect profiling. Phase I mechanism based proof-of-concept experimental clinical studies.
Working with CCBR speeds up and drives efficiencies in clinical trials by offering greater numbers of patients across fewer sites
A Global Footprint covering 16 dedicated Clinical Research Centers in high density population areas
Uniform SOPs enable the tightest possible adherence to study protocols and consistency across all CCBR sites
Real-Time tacking of subject enrolment and trial progress ensures sponsors have the most up to date information, all of the time
Centralised, standardised billing affords better visibility into trial costs for sponsors
